Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (281)	12/4/2001 5:21:22 PM
From: scaram(o)uche	Respond to of 1022

I said "license". I was talking about the subsequent deal, and I'm avoiding mention of the licensee for a reason.

To: Icebrg who wrote (281)	12/8/2001 2:44:52 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

IMPROVING THE EFFICACY OF ANTIBODY-BASED CANCER THERAPIES (From Nature reviews cancer - free but registration required) A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.... nature.com